uniQure sets course to US filing for Huntington gene therapy
Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.
Newsletters and Deep Dive digital magazine
Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.
Germany's government is reportedly scrapping plans to introduce a controversial system of variable rebates on medicines.
The FDA is due to deliver a verdict in February on Gilead's once-weekly pill for HIV PrEP, which could expand the options available to patients.
A study linking dispensing data to patient characteristics in England has exposed differences in medicine use across ethnic and socioeconomic groups.
Eisai has been given a grant from the UK that will support a £48m plan to add cold chain capabilities to its facility in Hatfield, Hertfordshire.
Editor's Picks
Newsletters and Deep Dive
digital magazine